While evaluating the individual effects of treatment groups (i.e., effects without background treatments) on visfatin concentrations and its relation to subclinical atherosclerosis, we found that patients undergoing monotherapy with statins or CCB had lower visfatin concentrations compared to the non-treatment group (2.49 ± 0.39 pg/mL and 1.91 ± 0.82 pg/mL vs. 3.18 ± 0.64 pg/mL, respectively) and patients using ACEI/ARB or β-blockers (3.37 ± 1.57 pg/mL and 3.44 ± 0.89 pg/mL, respectively). This evidence concerns the gene NAMPT and atherosclerosis.